Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
On July 31, 2026, the Health Resources and Services Administration published a revised Notice Regarding the 340B Rebate Model Pilot Program in the Federal Register. The pilot, scheduled to take
Summary The U.S. administration has threatened tariffs of up to 200% on imported generic drugs. Branded medicines have seen limited impact so far. In part, that is because 17 drugmakers
Summary About 20% of Americans taking a GLP-1 for weight loss are not using an FDA-approved product, according to a recent Gallup survey. Another 12% were unsure what they were
Summary GSK will discontinue camlipixant, the chronic cough treatment it gained through its acquisition of Bellus Health. Two pivotal trials produced conflicting results. One dose worked in one study and
Summary Eli Lilly is acquiring AtaiBeckley, a developer of psychedelic-derived medicines. The deal is valued at roughly $2.8 billion upfront. Additional milestone payments could push the total value toward $3.8
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Summary Zymeworks agreed to acquire Theravance Biopharma for $929 million, following the failure of ampreloxetine in neurogenic orthostatic hypotension. Consequently, Theravance entered a strategic review that identified its approved portfolio
Summary Ipsen announced the acquisition of Swiss biotech Memo Therapeutics on July 1, 2026. The deal is valued at up to $800 million, with €200 million upfront and more than
Summary Tennessee enacted the FAIR Rx Act, banning pharmacy benefit manager-owned pharmacies from operating in the state. Express Scripts and the PCMA filed separate lawsuits in June 2026 to block
Summary Eli Lilly halted 340B drug discount pricing for a group of non-compliant US hospitals on June 19, 2026. The company says it needs claims data to prevent fraud and